Greg Landsman sold Bristol-Myers Squibb Company (NYSE: BMY)
Greg Landsman (D-OH), a U.S. Representative, has disclosed 1 trade in Bristol-Myers Squibb Company (BMY) since 2025, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Greg Landsman sold $1,001 - $15,000 of Bristol-Myers Squibb Company (NYSE: BMY) on March 27, 2025. Since that trade, BMY is up +16.87% against the S&P 500 up +32.29%, an outperformance of -15.42%.
Data updated
Greg Landsman's BMY trades vs the price
BMY is up +16.87% since Greg Landsman sold on March 27, 2025, versus +32.29% for the S&P 500.
Performance since this trade
All Greg Landsman BMY trades
Greg Landsman & BMY trading FAQ
Is it legal for Greg Landsman to trade Bristol-Myers Squibb Company (BMY) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Bristol-Myers Squibb Company (BMY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Greg Landsman sell BMY?
Greg Landsman disclosed a sale of $1,001 - $15,000 of Bristol-Myers Squibb Company (BMY) on March 27, 2025, according to public STOCK Act filings.
How has BMY performed since Greg Landsman's trade?
Since Greg Landsman sold BMY on March 27, 2025, the stock is up +16.87%, versus +32.29% for the S&P 500 over the same period, an outperformance of -15.42%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional BMY trades?
Quantellect tracks every disclosed congressional trade in Bristol-Myers Squibb Company (BMY) on the Bristol-Myers Squibb Company congressional trading page, which aggregates filings across all members of Congress.
Greg Landsman's BMY tradesAll congressional filings for Bristol-Myers Squibb CompanyGreg Landsman's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.